NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

AUSCANN GROUP HOLDINGS LTD (AC8)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
AUSCANN GROUP HOLDINGS LTD27/01/2017
TW HOLDINGS LIMITED15/12/201127/01/2017
CRW HOLDINGS LIMITED24/06/201115/12/2011
COCKATOO RIDGE WINES LIMITED01/02/200224/06/2011
ADELAIDE SHARE INVESTMENTS LIMITED29/11/199501/02/2002
REDWEAVER INVESTMENTS LIMITED29/11/1995

Shareholder links

Our website ranking of AC8: rating 2
(2 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000AC89
Address: 1202 Hay Street West Perth WA 6005
Tel:  +61 8 6444 1720Fax: +61 8 6255 5031

Date first listed: 03/05/1989
Company Secretary: Rachel Kerr
Sector: Food, Beverage & Tobacco 
Activities: Branded and bulk wine sales

News & Events

Expand this box to read and print

The company releases a notice of cancellation of proposed issue of securities.

15/02/2024

The company releases a Supplementary Prospectus.

15/02/2024

The Board of Directors has resolved to withdraw the Share Purchase Plan offer as set out in the Company's prospectus announced to ASX and lodged with ASIC on 25 January 2024. The Board of AusCann decided to withdraw the SPP offer due to the potential implications the capital raising may cause for the Company should the Company apply to undertake a re-compliance with Chapters 1 and 2 of the ASX Listing Rules.

15/02/2024

The opening date of the SPP has been updated to 12 February 2024. The prospectus and application form will be sent to eligible shareholders on 12 February 2024 by either mail or email, depending on registered communication preferences with Computershare. Eligible shareholders are encouraged to read the prospectus lodged 25 January 2024 in its entirety prior to applying for new shares under the SPP.

05/02/2024

The company lodges its December 2023 Quarterly Activities and Cashflow Reports.

30/01/2024

The Company issues a prospectus for the offer of up to 62,500,000 New Shares to Eligible Shareholders at an issue price of $0.016 per New Share to raise up to $1,000,000 (before costs) under this Prospectus. Any New Shares not subscribed for under the SPP Offer will form the Shortfall. The offer to issue the Shortfall is a separate offer under this Prospectus.

25/01/2024

The company releases a notice of proposed issue of securities.

25/01/2024

The Company intends to offer a share purchase plan to existing eligible shareholders, being shareholders of the Company with a registered address in Australia and New Zealand recorded on the Company's share register at 5:00pm (AWST) on 24 January 2024. Eligible Shareholders will have the opportunity to acquire up to A$30,000 worth of AusCann ordinary shares, irrespective of the size of their holding, at an issue price of A$0.016 per New Share. The issue price represents a discount of 60% to $0.04, being the closing price of Shares on ASX on 29 August 2022. AusCann is targeting raising up to $1 million under the SPP Offer through the issue of approximately 62,500,000 New Shares. The Company has sufficient placement capacity under Listing Rule 7.1 to undertake the SPP Offer. Participation in the SPP Offer is optional.

25/01/2024

The Company has entered a new secured Loan Agreement with European Cannabis Corporation Limited to provide an additional €1m investment for HAPA Pharm BV (100% owned subsidiary of ECC) with the required working capital to launch the HAPA 2.0 products to market in Germany from January 2024. The loan agreement includes security as collateral. The fully paid ordinary shares of AusCann remain suspended from quotation on the official list of ASX and will remain suspended from quotation until the Company has re-complied with Chapters 1 and 2 of the Listing Rules. The Board have been actively seeking opportunities which would add value to the Company and enable the Company to seek re-quotation of its shares on the official list of ASX. The Board will continue to update the market as it progresses with evaluating a proposed acquisition, including acquisitions in the cannabis sector.

23/01/2024

The Company appoints Hall Chadwick WA Audit Pty Ltd as its auditor to replace PKF.

03/01/2024

The company releases the results of its AGM.

30/11/2023

The company lodges its September 2023 Quarterly Activities and Cashflow Reports.

31/10/2023

The annual general meeting of the Company will be held at the offices of Thomson Geer, Level 14, 60 Martin Place, Sydney, New South Wales on Thursday, 30 November 2023 at 9:00am (EDST).

27/10/2023

The company releases a letter to its shareholders regarding its annual general meeting.

27/10/2023

The company releases its Appendix 4G and Corporate Governance Statement.

27/10/2023

The company lodges its Annual Report.

27/10/2023

The company releases a notification of cessation of securities.

26/10/2023

The Company has completed an independent legal review of the loan agreements in place that provided funding to support the operations of European Cannabis Corporation Limited and its subsidiary HAPA Pharm BV, following the recent appointment of leading corporate legal firm Thomson Geer as its company solicitor. The Company has subsequently entered a new secured Loan Agreement with ECC that supersedes the previous loan agreement as set out in the Company's ASX releases and statutory accounts, and now includes security as collateral for the $8,050,000 secured loan facility. AusCann has subscribed for $1,250,000 of convertible notes pursuant to a new secured Convertible Note Deed and has provided ECC with a total of $1,250,000 through this arrangement.

25/10/2023

The Company's Annual General Meeting will be held on Thursday, 30 November 2023 at 9.00am (EDST) at the offices of Thomson Geer, Level 14, 60 Martin Place, Sydney, New South Wales. A valid nomination for the position of Director may be received by the Company not less than 35 business days before the date of the annual general meeting (12 October 2023).

15/09/2023

The company lodges its Appendix 4E and 30 June 2023 Preliminary Financial Report.

31/08/2023

The company lodges its June 2023 Quarterly Activities and Cashflow Reports.

31/07/2023

The Company has expanded its agreement with European Cannabis Corporation Limited that will now see AusCann sell and distribute EU GMP certified medicinal cannabis in Australia and New Zealand.AusCann becomes the exclusive agent for ECC's HAPA products in AU/NZ. This includes a diverse cannabinoid product portfolio of raw flower and standardised full spectrum extracts. ECC manufactures all medicinal products under German EU GMP licensed conditions. This expansion has not resulted in any additional consideration. ECC will also provide AusCann with all necessary regulatory support for the products supplied, including documentation required to satisfy compliance with Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 201.

31/07/2023

The company has completed settlement of the sale of its facility located at 11 Excellence Drive, Wangara, Western Australia. After the purchaser, Optral Pty Ltd, completed the due diligence period, the final purchase price was revised slightly to $6,740,000. Settlement was completed on Friday, 9 June 2023.

13/06/2023

The company lodges its March 2023 Quarterly Activities and Cashflow Reports.

28/04/2023

Auscann Operations Pty Ltd has entered into a conditional contract for the sale of its premises located at 11 Excellence Drive, Wangara WA 6075. The purchase price is $6,750,000 to Optral Pty Ltd and is expected to settle on 8 June 2023. LJ Hooker Commercial Perth negotiated the contract of sale through an on-market campaign on behalf of Auscann. Optral, who are active on the LJHC database, are private commercial property investors that own multiple commercial properties throughout Australia including Western Australia.

04/04/2023

AusCann has entered into a share sale agreement with Animal Health Holdings Pty Ltd to privatise its animal health business, CannPal Animal Therapeutics Pty Ltd, by divesting 52% of CannPal to AHH. AHH is a Special Purpose Vehicle which will assume the responsibility for all current and future expenses for the development and commercialisation of the animal health assets of CannPal. AHH will be controlled by AusCann's outgoing Chief Executive Officer, Mr Layton Mills, and the outgoing Chief Scientific Officer of AusCann, Dr Margaret Curtis. AusCann will retain a 48% free-carried interest in CannPal and has no obligation to fund CannPal. AusCann retains the right to re-acquire the shares in CannPal upon the failure of CannPal to reach agreed development and commercialisation milestones. The Partial Divestment enables CannPal to operate as an unencumbered and private animal health company better positioned to attract, secure and maintain strategic partnerships and resources for the continued development and commercialisation of AusCann's animal health assets. The Partial Divestment is a separate and independent transaction from the proposed transaction under Listing Rule 11.1, the subject of AusCann's suspension from trading.

10/03/2023

The company lodges its Appendix 4D and Half-Year Financial Report 31 December 2022.

28/02/2023

The company lodges its December 2022 Quarterly Activities and Cashflow Reports.

31/01/2023

The company releases the results of the Annual General Meeting.

30/11/2022

AusCann is expected to finalise an application in Q1 2023 to secure the relevant regulatory licences to enable the import of EU-GMP cannabis under the Term Sheet, following the changes to TGO93 in June, 2023. The company has submitted its R&D Tax Incentive Refund for the 2022 financial year and is expecting an estimated rebate of $1.1m in Q1 2023. It's expected that the AusCann's securities will remain suspended until AusCann has recompiled with Chapters 1 and 2 of the Listing Rules. The conditional contract of AusCann Operations for the sale of the property held by AusCann Ops at 11 Excellence Drive, Wangara WA 6065 has lapsed as a result of incomplete due diligence. The company remains in ongoing discussions with the purchaser and other interested parties.

30/11/2022

The company lodges its September 2022 Quarterly Activities and Cashflow Reports.

31/10/2022

The company's AGM will be held at 11.00am (EDST) on Wednesday, 30 November 2022 at the offices of K&L Gates, Level 31, 1 O'Connell Street, Sydney, New South Wales.

28/10/2022

The company lodges its Annual Report.

28/10/2022

The company lodges its Annual Financial Statements.

30/09/2022

The company lodges its Appendix 4G and Corporate Governance Statement.

30/09/2022

The company's AGM will be held on Wednesday, 30 November 2022 at 11.00am (EDST) at the offices of K&L Gates, Level 31, 1 O'Connell Street, Sydney, New South Wales. A valid nomination for the position of Director may be received by the Company not less than 35 business days before the date of the annual general meeting (12 October 2022).

30/09/2022

The Company and EuroCann have agreed to increase the facility provided by the Company under the Secured Loan Agreement by an additional A$3.75 million. Other than the additional advance, the terms of the Secured Loan Agreement remain as per the Company's announcement on 29 August 2022. AusCann Operations has entered into a conditional contract for the sale of the property held by AusCann Ops at 11 Excellence Drive, Wangara WA 6065. Under the Sale Contract, the purchase price for the Wangara Premises is $7,000,000 (as a going concern), and the proposed purchaser is Yolena Pty Ltd. The Sale Contract will automatically terminate if either the Finance Condition or the Due Diligence Condition are not satisfied within 30 days of the date of the Sale Contract.

09/09/2022

The securities of AusCann Group Holdings Ltd will be suspended from quotation immediately, at the request of AC8, pending the release of an announcement regarding a proposed material acquisition. ASX has exercised its discretion under Listing Rule 11.1.2 to require the Proposed Acquisition to be conditional on approval by AC8's ordinary security holders and under Listing Rule 11.1.3 to require AC8 to recomply with Chapters 1 and 2 of the Listing Rules. It is expected that AC8's securities will remain suspended until AC8 has recompiled with Chapters 1 and 2 of the Listing Rules.

31/08/2022

AusCann Group Holdings Ltd will be reinstated to Official Quotation from the commencement of trading on Friday, 3 February 2017, following the Company's re-compliance with Chapters 1 and 2 of the ASX Listing Rules pursuant to Listing Rule 11.1.3

01/02/2017

The company lodges its Appendix 4C - quarterly report.

31/01/2017

name changed from TW Holdings Limited

27/01/2017

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments

Their web site now does not exist. Very alarming for shareholders as this company sinks and also while their stock has been frozen now for many months with no action from ASIC. They have recently signed a sale agreement for their facility with the millions of dollars going towards a 'proposed' material acquisition and 'working' capital. 

08/04/2023 09:07:59

If you are looking for the Auscann ASX 

visit here :- https://www.kalkine.com.au/companies/auscann-group-holdings-ltd.aspx

25/07/2018 11:09:39

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    14/05/2021Geoff Starr100,000$0.115$11,500
    15/04/2021Max Johnston110,000$0.140$15,400
    04/03/2020Krista Bates95,000$0.220$20,900
    25/03/2019Paul MacLeman30,268$0.330$9,988
    08/03/2019Malcolm Washer144,000$0.403$57,996

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Andrew ChapmanNon Exec Chairman01/12/2023
    Layton MillsCEO18/03/2021
    Quentin MegsonCOO01/10/2018
    Brett MitchellIndependent Director29/06/2023
    Rob CliffordNon Exec Director01/04/2021

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Tod McGroutherChairman14/12/202101/12/2023
    Christopher MewsCFO01/12/201901/07/2023
    Krista BatesNon Exec Director20/12/201931/12/2022
    Charles AltshulerCFO29/03/202107/04/2022
    Geoff StarrNon Exec Director01/04/202114/12/2021
    Kate AdamsNon Exec Director01/04/202114/12/2021
    Max JohnstonChairman20/12/201915/11/2021
    Bruce McHarrieNon Exec Director02/06/201615/11/2021
    Nick WoolfCEO05/08/202018/03/2021
    Marcel Bonn-MillerNon Exec Director05/09/201903/10/2020
    Ido KanyonCEO22/05/201907/05/2020
    Cheryl EdwardesChairman11/05/201619/01/2020
    Paul MacLemanExecutive Director27/09/201804/11/2019
    Malcolm WasherNon Exec Chairman19/01/201728/10/2019
    Bruce LintonNon Exec Director02/06/201605/09/2019
    David PryceAlternate Director15/06/201705/09/2019
    Elaine DarbyManaging Director19/01/201731/12/2018
    Harry KarelisExecutive Director19/01/201715/12/2017
    David WheelerNon Exec Chairman18/11/201419/01/2017
    Nicholas CalderNon Exec Director18/11/201419/01/2017
    Simon TaylorNon Exec Director18/11/201419/01/2017
    Johann Jooste-JacobsDirector14/12/201218/11/2014
    Scott DouglasDirector14/12/201218/11/2014
    Craig AndersonDirector14/12/201218/11/2014
    Mark ClementsCompany Secretary05/06/201318/11/2014
    Stephen EvansNon Exec Director30/09/201014/12/2012
    Donald StephensNon Exec Director31/01/201114/12/2012
    Melvyn DrummondExecutive Director07/09/200514/12/2012
    Ivan LimbNon Exec Chairman30/01/200231/01/2011
    Stuart RichardsonNon Exec Chairman04/10/200730/09/2010
    Peter PerrinManaging Director01/05/200706/11/2009
    Nicholas LimbNon Exec Director30/01/200204/10/2007
    Richard EarlNon Exec Chairman30/01/200231/05/2006
    Christopher RobertsNon Exec Director30/01/200224/04/2006
    James LewisChairman01/03/199730/01/2002
    Geoffrey WilsonNon Exec Director11/11/199830/01/2002
    Julian GosseCompany Secretary10/08/200030/01/2002

    Date of first appointment, title may have changed.